Friday, 25 September 2026European Markets

DBV TECHNOLOGIES Stock Went Up By Over 10% So Far Today

Loading stream...

(vianews) - shares of dbv technologies (cac 40: dbv.pa) jumped by a staggering 10.27% to €3.31 at 13:57 est on wednesday, following the last session's downward trend. cac 40 is falling 0.07% to €7,334.28, following the last session's downward trend. this seems, so far, a somewhat down trend exchanging session today.

dbv technologies's last close was €3.00, 45.26% under its 52-week high of €5.48.

about dbv technologies

dbv technologies s.a., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. its lead product candidate is viaskin peanut, an immunotherapy product, which has completed phase iii clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. the milk-induced company is also developing viaskin milk that is in phase i/ii clinical trial for the treatment of immunoglobulin e (ige) mediated cow's milk protein allergy (cmpa); viaskin egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for bordetella pertussis. its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for crohn's disease, celiac disease, and type i diabetes. the company has a collaboration with nestlé health science to develop mag1c, a ready-to-use atopy patch test for the diagnosis of non-ige mediated cmpa in infants and toddlers. dbv technologies s.a. was incorporated in 2002 and is headquartered in montrouge, france.

earnings per share

as for profitability, dbv technologies has a trailing twelve months eps of €-2.447.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -42.99%.

growth estimates quarters

the company's growth estimates for the ongoing quarter and the next is 21.7% and 16.7%, respectively.

moving average

dbv technologies's value is way above its 50-day moving average of €2.79 and under its 200-day moving average of €3.53.

more news about dbv technologies (dbv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agents Scale Up Through Partnerships and Funding, But Data Readiness Lags Ambition
A wave of vertical AI-agent startups (Swarm, Veridox, Avallon AI, DA2, F2, Earthian, Meanwhile, Covecta, Penguin AI, Maisa AI) is being funded and profiled just as major infrastructure players — Microsoft/Mistral, Siemens/NVIDIA, and Manulife/Microsoft — cement enterprise AI governance and compute partnerships. Yet a Google Cloud report shows AI agents still lack access to the majority of company data (only 45% on average), and insider selling at incumbent C3.ai signals investor caution even as adoption intent (100% planned agentic AI use within two years) races ahead of actual data infrastructure.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,984
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,984 facts checked against source5,306 source documents archived
Query this data → isubstrate.com